Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients

Nutr Metab Cardiovasc Dis. 2016 Jul;26(7):581-589. doi: 10.1016/j.numecd.2016.03.008. Epub 2016 Mar 25.

Abstract

Background and aims: Vitamin D receptor activation (VDRA) ameliorates endothelial dysfunction in CKD patients but also increases phosphate and FGF-23, which may attenuate the beneficial effect of VDRA on endothelial function.

Methods and results: This is a pre-specified secondary analysis of the PENNY trial (NCT01680198) testing the effect of phosphate and FGF-23 on the flow mediated vasodilatory (FMD) response to paricalcitol (PCT, 2 μg/day) and placebo over a 12-weeks treatment period. Eighty-eight stage G3-4 CKD patients were randomized to PCT (n = 44) and Placebo (n = 44). Endothelial function was assessed by measuring endothelium dependent forearm blood flow (FBF) response to ischemia. The FMD response was by the 61% higher in PCT treated patients than in those on placebo (P = 0.01). Phosphate (+11%, P = 0.039), calcium (+3%, P = 0.01) and, particularly so, FGF23 (+164%, P < 0.001) increased in PCT treated patients. Changes in FMD by PCT associated inversely with phosphate (r = -0.37, P = 0.01) but were independent of FGF-23, calcium and PTH changes. The response to PCT was maximal in patients with no changes in phosphate (1st tertile), attenuated in those with mild-to-moderate rise in phosphate (2nd tertile) and abolished in those with the most pronounced phosphate increase (3rd tertile) (effect modification P = 0.009). No effect modification by FGF-23 and other variables was observed.

Conclusions: The beneficial effect of PCT on endothelial function in CKD is maximal in patients with no or minimal changes in phosphate and it is abolished in patients with a pronounced phosphate rise. These findings generate the hypothesis that the endothelium protective effect by VDRA may be potentiated by phosphate lowering interventions.

Keywords: CKD; Effect modification; Flow mediated vasodilation; Paricalcitol; Phosphate.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Biomarkers / blood
  • Brachial Artery / drug effects*
  • Brachial Artery / metabolism
  • Brachial Artery / physiopathology
  • Double-Blind Method
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology
  • Ergocalciferols / adverse effects
  • Ergocalciferols / therapeutic use*
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood
  • Forearm / blood supply*
  • Humans
  • Male
  • Middle Aged
  • Phosphates / blood*
  • Receptors, Calcitriol / agonists*
  • Receptors, Calcitriol / metabolism
  • Regional Blood Flow
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / diagnosis
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / physiopathology
  • Signal Transduction / drug effects
  • Time Factors
  • Treatment Outcome
  • Vasodilation / drug effects*
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / therapeutic use*

Substances

  • Biomarkers
  • Ergocalciferols
  • FGF23 protein, human
  • Phosphates
  • Receptors, Calcitriol
  • VDR protein, human
  • Vasodilator Agents
  • Fibroblast Growth Factors
  • paricalcitol
  • Fibroblast Growth Factor-23